Theranica announced that insurance coverage for Nerivio, its FDA-cleared migraine wearable, has now reached 158 million lives. It is now covered for half of the US insured population. Worn on the upper arm and controlled by a smartphone app, Nerivio uses remote electrical neuromodulation to activate the body's own pain-inhibitory pathways for both acute and preventive migraine treatment. Coverage has doubled over the past 15 months.